Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

BACKGROUND: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)‐high or mismatch repair‐deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. METHODS: We performed a single institution retrospective revi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Tucker, Matthew D., Zhu, Jason, Marin, Daniele, Gupta, Rajan T., Gupta, Santosh, Berry, William R., Ramalingam, Sundhar, Zhang, Tian, Harrison, Michael, Wu, Yuan, Healy, Patrick, Lisi, Stacey, George, Daniel J., Armstrong, Andrew J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712455/
https://ncbi.nlm.nih.gov/pubmed/31270961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2375
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados